


Amendments to the Claims:

Please amend the claims as shown in the following listing of claims, which will replace all prior versions and listings of claims in the application.

1.-6. (Canceled)

7. (New) A method comprising obtaining a compound of formula (I) or enantiomer, diastereomer, or salt thereof:



(I)

wherein:

R₁ is an atom of hydrogen or a linear or branched alkyl (C₁-C₆), alkenyl (C₁-C₆), or alkynyl (C₁-C₆) radical,

X is:

- an atom of oxygen, of sulphur or of selenium and Y is a single bond; or
- an atom of sulphur and Y is a CH₂ group;

Z is an atom of hydrogen or of halogen, or a linear or branched hydroxy or alkoxy group;

A is an imidazole, triazole or tetrazole nucleus; and

B is a phenyl, naphthyl, biphenyl or a monocyclic or bicyclic heteroaryl group having 5 to 10 bonds and comprising 1 to 3 heteroatoms, wherein the phenyl, naphthyl, biphenyl, or heteroaryl group is non-substituted or substituted by 1 to 3 alkyl (C₁-C₆), alkoxy (C₁-C₆), carboxy, formyl, amino, amido, ester, nitro, cyano, or trifluoromethyl, groups and/or halogens; and

administering the compound, enantiomer, diastereomer, or salt to a subject with cancer or psoriasis.

8. (New) The method of claim 7, wherein X is an atom of sulphur and Y is a CH₂ group substituted by one or two lower alkyl groups.


9. (New) The method of claim 7, wherein B is:

an unsubstituted benzene or benzene substituted in the meta or para position by a cyano or nitro group or an atom of chlorine; or
a pyridine heterocycle.
10. (New) The method of claim 7, wherein R₁ is an atom of hydrogen or a methyl group.
11. (New) The method of claim 7, wherein Z is an atom of hydrogen or a methoxy group.
12. (New) The method of claim 7, wherein A is a 1,3-imidazolyl or 1,2,4 triazolyl group.
13. (New) The method of claim 7, wherein the compound of formula (I) is:

5-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-1,3-benzoxazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-3-methyl-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-3-methyl-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-3-ethyl-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,4-benzoxazin-3(4*H*)-one;
6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-4-methyl-1,4-benzoxazin-3(4*H*)-one;
7-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-4-methyl-1,4-benzothiazin-3(4*H*)-one;
3-Ethyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
4-[(2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile;
4-[(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile;
4-[(3-Ethyl-2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile;
3-Methyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzoselenazol-2(3*H*)-one;
3-Ethyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzoselenazol-2(3*H*)-one;
4-[(3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile; or

4-[(3-Ethyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)(1H-1,2,4-triazol-1-yl)methyl] benzonitrile.

14. (New) The method of claim 7, wherein the subject has cancer.
15. (New) The method of claim 7, wherein the subject has psoriasis.
16. (New) The method of claim 7, wherein the subject is a human.
17. (New) A pharmaceutical composition comprising a compound of formula (I) or enantiomer, diastereomer, or salt thereof:



(I)

wherein:

R₁ is an atom of hydrogen or a linear or branched alkyl (C₁-C₆), alkenyl (C₁-C₆), or alkynyl (C₁-C₆) radical,

X is:

- an atom of oxygen, of sulphur or of selenium and Y is a single bond; or
- an atom of sulphur and Y is a CH₂ group;

Z is an atom of hydrogen or of halogen, or a linear or branched hydroxy or alkoxy group;

A is an imidazole, triazole or tetrazole nucleus; and

B is a phenyl, naphthyl, biphenyl or a monocyclic or bicyclic heteroaryl group having 5 to 10 bonds and comprising 1 to 3 heteroatoms, wherein the phenyl, naphthyl, biphenyl, or heteroaryl group is non-substituted or substituted by 1 to 3 alkyl (C₁-C₆), alkoxy (C₁-C₆), carboxy, formyl, amino, amido, ester, nitro, cyano, or trifluoromethyl, groups and/or halogens;

in a pharmaceutically acceptable formulation.

18. (New) The composition of claim 17, wherein X is an atom of sulphur and Y is a CH₂ group substituted by one or two lower alkyl groups.
19. (New) The composition of claim 17, wherein B is:

an unsubstituted benzene or benzene substituted in the meta or para position by a cyano or nitro group or an atom of chlorine; or a pyridine heterocycle.

20. (New) The composition of claim 17, wherein R₁ is an atom of hydrogen or a methyl group.
21. (New) The composition of claim 17, wherein Z is an atom of hydrogen or a methoxy group.
22. (New) The composition of claim 17, wherein A is a 1,3-imidazolyl or 1,2,4 triazolyl group.
23. (New) The composition of claim 17, wherein the compound of formula (I) is:

5-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-1,3-benzoxazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-3-methyl-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-3-methyl-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-3-ethyl-1,3-benzothiazol-2(3*H*)-one;
6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-1,4-benzoxazin-3(4*H*)-one;
6-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-4-methyl-1,4-benzoxazin-3(4*H*)-one;
7-[(4-Cyanophenyl)(1*H*-imidazol-1-yl)methyl]-4-methyl-1,4-benzothiazin-3(4*H*)-one;
3-Ethyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzothiazol-2(3*H*)-one;
4-[(2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile;
4-[(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile;
4-[(3-Ethyl-2-oxo-2,3-dihydro-1,3-benzoselenazol-6-yl)(1*H*-1,2,4-triazol-1-yl)methyl]benzonitrile;
3-Methyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzoselenazol-2(3*H*)-one;
3-Ethyl-6-[(4-nitrophenyl)(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-benzoselenazol-2(3*H*)-one;

4-[(3-Methyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)(1H-1,2,4-triazol-1-yl)methyl]
benzonitrile; or
4-[(3-Ethyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)(1H-1,2,4-triazol-1-yl)methyl]
benzonitrile.